Conventional Amphotericin B has been used successfully to treat systemic fungal infections in pregnant women with no obvious effects on the foetus, but only a small number of cases have been reported. Reproductive toxicity studies of Amphotericin B in rats and rabbits showed no evidence of embryotoxicity, foetotoxicity or teratogenicity. However, safety for use in pregnant or lactating women has not been established for Ampholip. Therefore, Ampholip should be administered to pregnant or lactating women only for life-threatening disease when the likely benefit exceeds the risk to the mother and foetus.